Drug intelligence / Profile preview

TME031

Development stage: Preclinical
Lead developer: TME Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

TME031 is a double-stranded RNA (dsRNA) oligonucleotide therapeutic being developed by TME Therapeutics for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is designed to target and knock down the expression of Carbohydrate Sulfotransferase 3 (CHST3), an enzyme involved in the biosynthesis of chondroitin sulfate. By modulating the sulfation patterns of glycosaminoglycans in the lung extracellular matrix, TME031 aims to address the underlying pathology of COPD. The program is currently in the preclinical stage of development.

Targets

SULT (Sulfotransferase family 2A member 1)

Beyond the preview

Go deeper on TME031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TME031.

Explore the full profile